HIK — Hikma Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedLarge CapContrarian

Annual income statement for Hikma Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IFRS	IFRS	IFRS	IFRS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,553	2,517	2,875	3,156	3,349
Cost of Revenue
Gross Profit	1,301	1,265	1,407	1,448	1,457
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	1,955	2,208	2,513	2,547	2,652
Operating Profit	598	309	362	609	697
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	544	233	281	455	602
Provision for Income Taxes
Net Income After Taxes	420	191	192	362	490
Minority Interest
Net Income Before Extraordinary Items
Net Income	421	188	190	359	485
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	421	188	190	359	485
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.66	2.03	2.21	1.9	2.5
Dividends per Share